English

SUNSHINE BIOPHARMA INC.

EDGAR

SBFM Current report (8-K) · filed 2026-10-14

Annual consolidated revenue for 2025: about USD 36.31M, using the latest reported figures. The previous period, 2024, was about USD 34.87M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

9.26 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 9263687 USD Source

Operating margin

-17.41%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -1612858 USD Source
Revenue: 9263687 USD Source

Operating cash flow

-918 thousand USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -2990077 USD Source
Operating Cash Flow: -2072100 USD Source

Free cash flow

-925 thousand USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -2990077 USD Source
Operating Cash Flow: -2072100 USD Source
Capital Expenditure: 12144 USD Source
Capital Expenditure: 5129 USD Source

Cash and cash equivalents: 16.3 million USD 2023-12-31 Source
Exact value

16292347 USD
Long-term debt including current maturities: 2.05 million USD 2021-06-30 Source
Exact value

2054215 USD
Shares outstanding: 2.39 million shares 2026-06-30 Source
Exact value

2388516 shares

Reported share-count change

-47.57% · -2.17 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

4555945 shares · 2025-06-30· Source
2388516 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

35.3 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 9417179 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 36305891 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 27728750 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 8088765 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 9263687 USD · 2026-04-01 – 2026-06-30 Source

Net income

-5.83 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -883820 USD · 2025-07-01 – 2025-09-30 Source
Net income: -5975352 USD · 2025-01-01 – 2025-12-31 Source
Net income: -3834425 USD · 2025-01-01 – 2025-09-30 Source
Net income: -1243869 USD · 2026-01-01 – 2026-03-31 Source
Net income: -1564048 USD · 2026-04-01 – 2026-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-14.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 10 of 11 periods available· newest 2025-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 11 of 11 periods available· newest 2025-12-31
Total assets: 10 of 11 periods available· newest 2025-12-31
Total liabilities: 10 of 11 periods available· newest 2025-12-31
Current assets: 10 of 11 periods available· newest 2025-12-31
Current liabilities: 10 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 8 of 11 periods available· newest 2023-12-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2020-12-31
Shares outstanding: 10 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+4.1%

Prior period

USD 34.87 million

2024-01-01 – 2024-12-31
Current period

USD 36.31 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

36305891 − 34874283 = 1431608 USD

34874283 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
36305891 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · SUNSHINE BIOPHARMA INC. · 2025-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Year-over-year change in Revenue: 1431608 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 36305891 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316826002644/sunshine_i10k-123125.htm#418670 Filing: 000168316826002644 Input fundies:Revenue: 34874283 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316826002644/sunshine_i10k-123125.htm#419281 Filing: 000168316826002644
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 841,236

Prior period

−USD 5.13 million

2024-01-01 – 2024-12-31
Current period

−USD 5.98 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-5975352 − -5134116 = -841236 USD

-5134116 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-5975352 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · SUNSHINE BIOPHARMA INC. · 2025-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Year-over-year change in Net income: -841236 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -5975352 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316826002644/sunshine_i10k-123125.htm#471851 Filing: 000168316826002644 Input fundies:NetIncome: -5134116 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316826002644/sunshine_i10k-123125.htm#472229 Filing: 000168316826002644
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 7.19 million

Prior period

−USD 12.52 million

2024-01-01 – 2024-12-31
Current period

−USD 5.33 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-5331073 − -12524779 = 7193706 USD

-12524779 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-5331073 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · SUNSHINE BIOPHARMA INC. · 2025-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Year-over-year change in Operating cash flow: 7193706 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -5331073 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316826002644/sunshine_i10k-123125.htm#485102 Filing: 000168316826002644 Input fundies:OperatingCashFlow: -12524779 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316826002644/sunshine_i10k-123125.htm#485575 Filing: 000168316826002644
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-89.5%

Prior period

USD 1.66 million

2024-01-01 – 2024-12-31
Current period

USD 174,491

2025-01-01 – 2025-12-31

Exact inputs and evidence

174491 − 1657055 = -1482564 USD

1657055 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
174491 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · SUNSHINE BIOPHARMA INC. · 2025-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Year-over-year change in Capital expenditure: -1482564 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 174491 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316826002644/sunshine_i10k-123125.htm#488159 Filing: 000168316826002644 Input fundies:CapitalExpenditure: 1657055 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316826002644/sunshine_i10k-123125.htm#488621 Filing: 000168316826002644
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 36.31 million 100% of revenue
Operating costs Derived USD 42.53 million 117% of revenue
Operating income −USD 6.23 million −17% of revenue
Tax, interest and other Derived −USD 251,677 −0.7% of revenue
Net income −USD 5.98 million −16% of revenue

Cash

Operating cash flow −USD 5.33 million −15% of revenue
Capital expenditure USD 174,491 0.5% of revenue
Free cash flow Derived −USD 5.51 million −15% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Not shown: operating income or net income is not reported.
2017 Not shown: operating income or net income is not reported.
2018 Not shown: operating income or net income is not reported.
2019 Operating loss: operating costs were 3,138% of revenue.
2020 Operating loss: operating costs were 908% of revenue.
2021 Operating loss: operating costs were 1,168% of revenue.
2022 Operating loss: operating costs were 721% of revenue.
2023 Operating loss: operating costs were 120% of revenue.
2024 Operating loss: operating costs were 117% of revenue.
2025 Operating loss: operating costs were 117% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	0	993108 Derived	-993108	2503579 Derived	-3496687	-317621 Derived	Source 2016-01-01 – 2016-12-31: 0 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -993108 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -3496687 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -314182 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 3439 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	0	857190 Derived	-857190	183046 Derived	-1040236	-547238 Derived	Source 2017-01-01 – 2017-12-31: 0 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -857190 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -1040236 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -543520 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 3718 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	0	1164290 Derived	-1164290	991865 Derived	-2156155	-531656 Derived	Source 2018-01-01 – 2018-12-31: 0 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -1164290 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -2156155 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -512806 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 18850 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	21121	662757 Derived	-641636	1018655 Derived	-1660291	-496658 Derived	Source 2019-01-01 – 2019-12-31: 21121 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -641636 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -1660291 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -495798 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 860 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	71410	648284 Derived	-576874	2207217 Derived	-2784091	-658490 Derived	Source 2020-01-01 – 2020-12-31: 71410 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -576874 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -2784091 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -657299 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 1191 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	228426	2668560 Derived	-2440134	9996313 Derived	-12436447	-1829128 Derived	Source 2021-01-01 – 2021-12-31: 228426 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -2440134 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -12436447 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -1829128 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: -0 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	4345603	31346353 Derived	-27000750	-256310 Derived	-26744440	-5442340 Derived	Source 2022-01-01 – 2022-12-31: 4345603 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -27000750 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -26744440 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -5248358 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 193982 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	24092787	28878086 Derived	-4785299	-279255 Derived	-4506044	-8857362 Derived	Source 2023-01-01 – 2023-12-31: 24092787 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -4785299 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -4506044 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -8775111 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 82251 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	34874283	40686404 Derived	-5812121	-678005 Derived	-5134116	-14181834 Derived	Source 2024-01-01 – 2024-12-31: 34874283 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -5812121 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -5134116 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -12524779 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 1657055 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	36305891	42532920 Derived	-6227029	-251677 Derived	-5975352	-5505564 Derived	Source 2025-01-01 – 2025-12-31: 36305891 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -6227029 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -5975352 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -5331073 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 174491 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 36.3M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	0	Revenue: 0 Open source
20172017-12-31	Revenue	0	Revenue: 0 Open source
20182018-12-31	Revenue	0	Revenue: 0 Open source
20192019-12-31	Revenue	21121	Revenue: 21121 Open source
20202020-12-31	Revenue	71410	Revenue: 71410 Open source
20212021-12-31	Revenue	228426	Revenue: 228426 Open source
20222022-12-31	Revenue	4345603	Revenue: 4345603 Open source
20232023-12-31	Revenue	24092787	Revenue: 24092787 Open source
20242024-12-31	Revenue	34874283	Revenue: 34874283 Open source
20252025-12-31	Revenue	36305891	Revenue: 36305891 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

4.1% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20172017-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20182018-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20192019-12-31	Year over year	No prior comparable period	Revenue: 21121 Open source Revenue: 0 Open source
20202020-12-31	Year over year	238.1%	Revenue: 71410 Open source Revenue: 21121 Open source
20212021-12-31	Year over year	219.9%	Revenue: 228426 Open source Revenue: 71410 Open source
20222022-12-31	Year over year	1,802.4%	Revenue: 4345603 Open source Revenue: 228426 Open source
20232023-12-31	Year over year	454.4%	Revenue: 24092787 Open source Revenue: 4345603 Open source
20242024-12-31	Year over year	44.7%	Revenue: 34874283 Open source Revenue: 24092787 Open source
20252025-12-31	Year over year	4.1%	Revenue: 36305891 Open source Revenue: 34874283 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -17.2% 2025

Net margin -16.5% 2025

Free cash flow margin -15.2% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	Not reported	Operating Income: -993108 Open source Revenue: 0 Open source
20172017-12-31	Operating margin	Not reported	Operating Income: -857190 Open source Revenue: 0 Open source
20182018-12-31	Operating margin	Not reported	Operating Income: -1164290 Open source Revenue: 0 Open source
20192019-12-31	Operating margin	-3,037.9%	Operating Income: -641636 Open source Revenue: 21121 Open source
20202020-12-31	Operating margin	-807.8%	Operating Income: -576874 Open source Revenue: 71410 Open source
20212021-12-31	Operating margin	-1,068.2%	Operating Income: -2440134 Open source Revenue: 228426 Open source
20222022-12-31	Operating margin	-621.3%	Operating Income: -27000750 Open source Revenue: 4345603 Open source
20232023-12-31	Operating margin	-19.9%	Operating Income: -4785299 Open source Revenue: 24092787 Open source
20242024-12-31	Operating margin	-16.7%	Operating Income: -5812121 Open source Revenue: 34874283 Open source
20252025-12-31	Operating margin	-17.2%	Operating Income: -6227029 Open source Revenue: 36305891 Open source
20162016-12-31	Net margin	Not reported	Net Income: -3496687 Open source Revenue: 0 Open source
20172017-12-31	Net margin	Not reported	Net Income: -1040236 Open source Revenue: 0 Open source
20182018-12-31	Net margin	Not reported	Net Income: -2156155 Open source Revenue: 0 Open source
20192019-12-31	Net margin	-7,860.9%	Net Income: -1660291 Open source Revenue: 21121 Open source
20202020-12-31	Net margin	-3,898.7%	Net Income: -2784091 Open source Revenue: 71410 Open source
20212021-12-31	Net margin	-5,444.4%	Net Income: -12436447 Open source Revenue: 228426 Open source
20222022-12-31	Net margin	-615.4%	Net Income: -26744440 Open source Revenue: 4345603 Open source
20232023-12-31	Net margin	-18.7%	Net Income: -4506044 Open source Revenue: 24092787 Open source
20242024-12-31	Net margin	-14.7%	Net Income: -5134116 Open source Revenue: 34874283 Open source
20252025-12-31	Net margin	-16.5%	Net Income: -5975352 Open source Revenue: 36305891 Open source
20162016-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -314182 Open source Capital Expenditure: 3439 Open source
20172017-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -543520 Open source Capital Expenditure: 3718 Open source
20182018-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -512806 Open source Capital Expenditure: 18850 Open source
20192019-12-31	Free cash flow margin	-2,351.5%	Revenue: 21121 Open source Operating Cash Flow: -495798 Open source Capital Expenditure: 860 Open source
20202020-12-31	Free cash flow margin	-922.1%	Revenue: 71410 Open source Operating Cash Flow: -657299 Open source Capital Expenditure: 1191 Open source
20212021-12-31	Free cash flow margin	-800.8%	Revenue: 228426 Open source Operating Cash Flow: -1829128 Open source Capital Expenditure: -0 Open source
20222022-12-31	Free cash flow margin	-125.2%	Revenue: 4345603 Open source Operating Cash Flow: -5248358 Open source Capital Expenditure: 193982 Open source
20232023-12-31	Free cash flow margin	-36.8%	Revenue: 24092787 Open source Operating Cash Flow: -8775111 Open source Capital Expenditure: 82251 Open source
20242024-12-31	Free cash flow margin	-40.7%	Revenue: 34874283 Open source Operating Cash Flow: -12524779 Open source Capital Expenditure: 1657055 Open source
20252025-12-31	Free cash flow margin	-15.2%	Revenue: 36305891 Open source Operating Cash Flow: -5331073 Open source Capital Expenditure: 174491 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -5.3M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	-314182	Operating Cash Flow: -314182 Open source
20172017-12-31	Operating cash flow	-543520	Operating Cash Flow: -543520 Open source
20182018-12-31	Operating cash flow	-512806	Operating Cash Flow: -512806 Open source
20192019-12-31	Operating cash flow	-495798	Operating Cash Flow: -495798 Open source
20202020-12-31	Operating cash flow	-657299	Operating Cash Flow: -657299 Open source
20212021-12-31	Operating cash flow	-1829128	Operating Cash Flow: -1829128 Open source
20222022-12-31	Operating cash flow	-5248358	Operating Cash Flow: -5248358 Open source
20232023-12-31	Operating cash flow	-8775111	Operating Cash Flow: -8775111 Open source
20242024-12-31	Operating cash flow	-12524779	Operating Cash Flow: -12524779 Open source
20252025-12-31	Operating cash flow	-5331073	Operating Cash Flow: -5331073 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -5.5M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	-317621	Operating Cash Flow: -314182 Open source Capital Expenditure: 3439 Open source
20172017-12-31	Free cash flow	-547238	Operating Cash Flow: -543520 Open source Capital Expenditure: 3718 Open source
20182018-12-31	Free cash flow	-531656	Operating Cash Flow: -512806 Open source Capital Expenditure: 18850 Open source
20192019-12-31	Free cash flow	-496658	Operating Cash Flow: -495798 Open source Capital Expenditure: 860 Open source
20202020-12-31	Free cash flow	-658490	Operating Cash Flow: -657299 Open source Capital Expenditure: 1191 Open source
20212021-12-31	Free cash flow	-1829128	Operating Cash Flow: -1829128 Open source Capital Expenditure: -0 Open source
20222022-12-31	Free cash flow	-5442340	Operating Cash Flow: -5248358 Open source Capital Expenditure: 193982 Open source
20232023-12-31	Free cash flow	-8857362	Operating Cash Flow: -8775111 Open source Capital Expenditure: 82251 Open source
20242024-12-31	Free cash flow	-14181834	Operating Cash Flow: -12524779 Open source Capital Expenditure: 1657055 Open source
20252025-12-31	Free cash flow	-5505564	Operating Cash Flow: -5331073 Open source Capital Expenditure: 174491 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

23.4% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Liabilities / assets	425.6%	Total Liabilities: 274104 Open source Total Assets: 64404 Open source
20172017-12-31	Liabilities / assets	322.7%	Total Liabilities: 830848 Open source Total Assets: 257485 Open source
20182018-12-31	Liabilities / assets	104.9%	Total Liabilities: 1202324 Open source Total Assets: 1146571 Open source
20192019-12-31	Liabilities / assets	849.3%	Total Liabilities: 833527 Open source Total Assets: 98142 Open source
20202020-12-31	Liabilities / assets	191.3%	Total Liabilities: 2000311 Open source Total Assets: 1045474 Open source
20212021-12-31	Liabilities / assets	90.4%	Total Liabilities: 1991229 Open source Total Assets: 2202891 Open source
20222022-12-31	Liabilities / assets	26%	Total Liabilities: 7616278 Open source Total Assets: 29243848 Open source
20232023-12-31	Liabilities / assets	22.5%	Total Liabilities: 6139600 Open source Total Assets: 27346961 Open source
20242024-12-31	Liabilities / assets	23.1%	Total Liabilities: 7059638 Open source Total Assets: 30560392 Open source
20252025-12-31	Liabilities / assets	23.4%	Total Liabilities: 7040707 Open source Total Assets: 30079167 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

4.17× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	0.21×	Current Assets: 58460 Open source Current Liabilities: 274104 Open source
20172017-12-31	Current assets / current liabilities	0.16×	Current Assets: 117199 Open source Current Liabilities: 751138 Open source
20182018-12-31	Current assets / current liabilities	1.21×	Current Assets: 1101447 Open source Current Liabilities: 912477 Open source
20192019-12-31	Current assets / current liabilities	0.08×	Current Assets: 65686 Open source Current Liabilities: 833527 Open source
20202020-12-31	Current assets / current liabilities	0.98×	Current Assets: 1025943 Open source Current Liabilities: 1051305 Open source
20212021-12-31	Current assets / current liabilities	24.07×	Current Assets: 2195830 Open source Current Liabilities: 91229 Open source
20222022-12-31	Current assets / current liabilities	3.94×	Current Assets: 27312334 Open source Current Liabilities: 6931014 Open source
20232023-12-31	Current assets / current liabilities	4.48×	Current Assets: 24890055 Open source Current Liabilities: 5551836 Open source
20242024-12-31	Current assets / current liabilities	4.11×	Current Assets: 25966349 Open source Current Liabilities: 6314914 Open source
20252025-12-31	Current assets / current liabilities	4.17×	Current Assets: 26853581 Open source Current Liabilities: 6443922 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 3.5 million Exact value Exact value: -3496687 USD 2016-01-01 – 2016-12-31: -3496687 USD Inspect Net Income Open source Share or cite Citation for Net Income · SUNSHINE BIOPHARMA INC. · 2016-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Net Income: -3496687 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -3496687 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000165495418010915/sbfm-20180630.xml#52957 Filing: 000165495418010915 The citation records this snapshot. The page link may show a newer release later.	−USD 314,182 Exact value Exact value: -314182 USD 2016-01-01 – 2016-12-31: -314182 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SUNSHINE BIOPHARMA INC. · 2016-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Operating Cash Flow: -314182 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -314182 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000165495418010915/sbfm-20180630.xml#63539 Filing: 000165495418010915 The citation records this snapshot. The page link may show a newer release later.	USD 3,439 Exact value Exact value: 3439 USD 2016-01-01 – 2016-12-31: 3439 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SUNSHINE BIOPHARMA INC. · 2016-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Capital Expenditure: 3439 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3439 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000165495418010915/sbfm-20180630.xml#64272 Filing: 000165495418010915 The citation records this snapshot. The page link may show a newer release later.	−USD 317,621 Calculation and evidence -314182 − 3439 USD Exact free cash flow: -317621 USD 2016-01-01 – 2016-12-31: -314182 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 3439 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SUNSHINE BIOPHARMA INC. · 2016-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Free cash flow: -317621 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -314182 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000165495418010915/sbfm-20180630.xml#63539 Filing: 000165495418010915 Input fundies:CapitalExpenditure: 3439 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000165495418010915/sbfm-20180630.xml#64272 Filing: 000165495418010915 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 1.04 million Exact value Exact value: -1040236 USD 2017-01-01 – 2017-12-31: -1040236 USD Inspect Net Income Open source Share or cite Citation for Net Income · SUNSHINE BIOPHARMA INC. · 2017-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Net Income: -1040236 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -1040236 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000165495419004354/sbfm-20181231.xml#57366 Filing: 000165495419004354 The citation records this snapshot. The page link may show a newer release later.	−USD 543,520 Exact value Exact value: -543520 USD 2017-01-01 – 2017-12-31: -543520 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SUNSHINE BIOPHARMA INC. · 2017-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Operating Cash Flow: -543520 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -543520 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000165495419004354/sbfm-20181231.xml#61869 Filing: 000165495419004354 The citation records this snapshot. The page link may show a newer release later.	USD 3,718 Exact value Exact value: 3718 USD 2017-01-01 – 2017-12-31: 3718 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SUNSHINE BIOPHARMA INC. · 2017-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Capital Expenditure: 3718 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3718 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000165495419004354/sbfm-20181231.xml#62235 Filing: 000165495419004354 The citation records this snapshot. The page link may show a newer release later.	−USD 547,238 Calculation and evidence -543520 − 3718 USD Exact free cash flow: -547238 USD 2017-01-01 – 2017-12-31: -543520 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 3718 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SUNSHINE BIOPHARMA INC. · 2017-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Free cash flow: -547238 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -543520 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000165495419004354/sbfm-20181231.xml#61869 Filing: 000165495419004354 Input fundies:CapitalExpenditure: 3718 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000165495419004354/sbfm-20181231.xml#62235 Filing: 000165495419004354 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 2.16 million Exact value Exact value: -2156155 USD 2018-01-01 – 2018-12-31: -2156155 USD Inspect Net Income Open source Share or cite Citation for Net Income · SUNSHINE BIOPHARMA INC. · 2018-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Net Income: -2156155 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2156155 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000165495420004731/sbfm-20191231.xml#76472 Filing: 000165495420004731 The citation records this snapshot. The page link may show a newer release later.	−USD 512,806 Exact value Exact value: -512806 USD 2018-01-01 – 2018-12-31: -512806 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SUNSHINE BIOPHARMA INC. · 2018-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Operating Cash Flow: -512806 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -512806 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000165495420004731/sbfm-20191231.xml#53112 Filing: 000165495420004731 The citation records this snapshot. The page link may show a newer release later.	USD 18,850 Exact value Exact value: 18850 USD 2018-01-01 – 2018-12-31: 18850 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SUNSHINE BIOPHARMA INC. · 2018-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Capital Expenditure: 18850 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 18850 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000165495420004731/sbfm-20191231.xml#53791 Filing: 000165495420004731 The citation records this snapshot. The page link may show a newer release later.	−USD 531,656 Calculation and evidence -512806 − 18850 USD Exact free cash flow: -531656 USD 2018-01-01 – 2018-12-31: -512806 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 18850 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SUNSHINE BIOPHARMA INC. · 2018-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Free cash flow: -531656 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -512806 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000165495420004731/sbfm-20191231.xml#53112 Filing: 000165495420004731 Input fundies:CapitalExpenditure: 18850 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000165495420004731/sbfm-20191231.xml#53791 Filing: 000165495420004731 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 1.66 million Exact value Exact value: -1660291 USD 2019-01-01 – 2019-12-31: -1660291 USD Inspect Net Income Open source Share or cite Citation for Net Income · SUNSHINE BIOPHARMA INC. · 2019-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Net Income: -1660291 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -1660291 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000165495421003507/sbfm-20201231.xml#45536 Filing: 000165495421003507 The citation records this snapshot. The page link may show a newer release later.	−USD 495,798 Exact value Exact value: -495798 USD 2019-01-01 – 2019-12-31: -495798 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SUNSHINE BIOPHARMA INC. · 2019-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Operating Cash Flow: -495798 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -495798 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000165495421003507/sbfm-20201231.xml#57699 Filing: 000165495421003507 The citation records this snapshot. The page link may show a newer release later.	USD 860 Exact value Exact value: 860 USD 2019-01-01 – 2019-12-31: 860 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SUNSHINE BIOPHARMA INC. · 2019-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Capital Expenditure: 860 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 860 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000165495421003507/sbfm-20201231.xml#58445 Filing: 000165495421003507 The citation records this snapshot. The page link may show a newer release later.	−USD 496,658 Calculation and evidence -495798 − 860 USD Exact free cash flow: -496658 USD 2019-01-01 – 2019-12-31: -495798 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 860 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SUNSHINE BIOPHARMA INC. · 2019-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Free cash flow: -496658 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -495798 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000165495421003507/sbfm-20201231.xml#57699 Filing: 000165495421003507 Input fundies:CapitalExpenditure: 860 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000165495421003507/sbfm-20201231.xml#58445 Filing: 000165495421003507 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 2.78 million Exact value Exact value: -2784091 USD 2020-01-01 – 2020-12-31: -2784091 USD Inspect Net Income Open source Share or cite Citation for Net Income · SUNSHINE BIOPHARMA INC. · 2020-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Net Income: -2784091 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2784091 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316822001788/sunshine_i10k-123121.htm#562161 Filing: 000168316822001788 The citation records this snapshot. The page link may show a newer release later.	−USD 657,299 Exact value Exact value: -657299 USD 2020-01-01 – 2020-12-31: -657299 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SUNSHINE BIOPHARMA INC. · 2020-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Operating Cash Flow: -657299 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -657299 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316822001788/sunshine_i10k-123121.htm#573795 Filing: 000168316822001788 The citation records this snapshot. The page link may show a newer release later.	USD 1,191 Exact value Exact value: 1191 USD 2020-01-01 – 2020-12-31: 1191 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SUNSHINE BIOPHARMA INC. · 2020-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Capital Expenditure: 1191 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1191 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316822001788/sunshine_i10k-123121.htm#576678 Filing: 000168316822001788 The citation records this snapshot. The page link may show a newer release later.	−USD 658,490 Calculation and evidence -657299 − 1191 USD Exact free cash flow: -658490 USD 2020-01-01 – 2020-12-31: -657299 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 1191 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SUNSHINE BIOPHARMA INC. · 2020-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Free cash flow: -658490 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -657299 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316822001788/sunshine_i10k-123121.htm#573795 Filing: 000168316822001788 Input fundies:CapitalExpenditure: 1191 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316822001788/sunshine_i10k-123121.htm#576678 Filing: 000168316822001788 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 12.44 million Exact value Exact value: -12436447 USD 2021-01-01 – 2021-12-31: -12436447 USD Inspect Net Income Open source Share or cite Citation for Net Income · SUNSHINE BIOPHARMA INC. · 2021-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Net Income: -12436447 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -12436447 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316823002128/sunshine_i10k-123122.htm#847551 Filing: 000168316823002128 The citation records this snapshot. The page link may show a newer release later.	−USD 1.83 million Exact value Exact value: -1829128 USD 2021-01-01 – 2021-12-31: -1829128 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SUNSHINE BIOPHARMA INC. · 2021-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Operating Cash Flow: -1829128 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1829128 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316823002128/sunshine_i10k-123122.htm#532049 Filing: 000168316823002128 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: -0 USD 2021-01-01 – 2021-12-31: -0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SUNSHINE BIOPHARMA INC. · 2021-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Capital Expenditure: -0 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: -0 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316823002128/sunshine_i10k-123122.htm#542598 Filing: 000168316823002128 The citation records this snapshot. The page link may show a newer release later.	−USD 1.83 million Calculation and evidence -1829128 − -0 USD Exact free cash flow: -1829128 USD 2021-01-01 – 2021-12-31: -1829128 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: -0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SUNSHINE BIOPHARMA INC. · 2021-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Free cash flow: -1829128 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1829128 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316823002128/sunshine_i10k-123122.htm#532049 Filing: 000168316823002128 Input fundies:CapitalExpenditure: -0 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316823002128/sunshine_i10k-123122.htm#542598 Filing: 000168316823002128 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 26.74 million Exact value Exact value: -26744440 USD 2022-01-01 – 2022-12-31: -26744440 USD Inspect Net Income Open source Share or cite Citation for Net Income · SUNSHINE BIOPHARMA INC. · 2022-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Net Income: -26744440 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -26744440 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316825000107/sunshine_s3.htm#649816 Filing: 000168316825000107 The citation records this snapshot. The page link may show a newer release later.	−USD 5.25 million Exact value Exact value: -5248358 USD 2022-01-01 – 2022-12-31: -5248358 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SUNSHINE BIOPHARMA INC. · 2022-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Operating Cash Flow: -5248358 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5248358 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316825000107/sunshine_s3.htm#339297 Filing: 000168316825000107 The citation records this snapshot. The page link may show a newer release later.	USD 193,982 Exact value Exact value: 193982 USD 2022-01-01 – 2022-12-31: 193982 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SUNSHINE BIOPHARMA INC. · 2022-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Capital Expenditure: 193982 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 193982 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316825000107/sunshine_s3.htm#349009 Filing: 000168316825000107 The citation records this snapshot. The page link may show a newer release later.	−USD 5.44 million Calculation and evidence -5248358 − 193982 USD Exact free cash flow: -5442340 USD 2022-01-01 – 2022-12-31: -5248358 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 193982 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SUNSHINE BIOPHARMA INC. · 2022-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Free cash flow: -5442340 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -5248358 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316825000107/sunshine_s3.htm#339297 Filing: 000168316825000107 Input fundies:CapitalExpenditure: 193982 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316825000107/sunshine_s3.htm#349009 Filing: 000168316825000107 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 4.51 million Exact value Exact value: -4506044 USD 2023-01-01 – 2023-12-31: -4506044 USD Inspect Net Income Open source Share or cite Citation for Net Income · SUNSHINE BIOPHARMA INC. · 2023-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Net Income: -4506044 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -4506044 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316825002184/sunshine_i10k-123124.htm#745230 Filing: 000168316825002184 The citation records this snapshot. The page link may show a newer release later.	−USD 8.78 million Exact value Exact value: -8775111 USD 2023-01-01 – 2023-12-31: -8775111 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SUNSHINE BIOPHARMA INC. · 2023-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Operating Cash Flow: -8775111 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -8775111 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316825002184/sunshine_i10k-123124.htm#440109 Filing: 000168316825002184 The citation records this snapshot. The page link may show a newer release later.	USD 82,251 Exact value Exact value: 82251 USD 2023-01-01 – 2023-12-31: 82251 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SUNSHINE BIOPHARMA INC. · 2023-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Capital Expenditure: 82251 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 82251 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316825002184/sunshine_i10k-123124.htm#444082 Filing: 000168316825002184 The citation records this snapshot. The page link may show a newer release later.	−USD 8.86 million Calculation and evidence -8775111 − 82251 USD Exact free cash flow: -8857362 USD 2023-01-01 – 2023-12-31: -8775111 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 82251 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SUNSHINE BIOPHARMA INC. · 2023-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Free cash flow: -8857362 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -8775111 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316825002184/sunshine_i10k-123124.htm#440109 Filing: 000168316825002184 Input fundies:CapitalExpenditure: 82251 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316825002184/sunshine_i10k-123124.htm#444082 Filing: 000168316825002184 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 5.13 million Exact value Exact value: -5134116 USD 2024-01-01 – 2024-12-31: -5134116 USD Inspect Net Income Open source Share or cite Citation for Net Income · SUNSHINE BIOPHARMA INC. · 2024-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Net Income: -5134116 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -5134116 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316826002644/sunshine_i10k-123125.htm#472229 Filing: 000168316826002644 The citation records this snapshot. The page link may show a newer release later.	−USD 12.52 million Exact value Exact value: -12524779 USD 2024-01-01 – 2024-12-31: -12524779 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SUNSHINE BIOPHARMA INC. · 2024-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Operating Cash Flow: -12524779 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12524779 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316826002644/sunshine_i10k-123125.htm#485575 Filing: 000168316826002644 The citation records this snapshot. The page link may show a newer release later.	USD 1.66 million Exact value Exact value: 1657055 USD 2024-01-01 – 2024-12-31: 1657055 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SUNSHINE BIOPHARMA INC. · 2024-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Capital Expenditure: 1657055 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1657055 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316826002644/sunshine_i10k-123125.htm#488621 Filing: 000168316826002644 The citation records this snapshot. The page link may show a newer release later.	−USD 14.18 million Calculation and evidence -12524779 − 1657055 USD Exact free cash flow: -14181834 USD 2024-01-01 – 2024-12-31: -12524779 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 1657055 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SUNSHINE BIOPHARMA INC. · 2024-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Free cash flow: -14181834 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12524779 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316826002644/sunshine_i10k-123125.htm#485575 Filing: 000168316826002644 Input fundies:CapitalExpenditure: 1657055 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316826002644/sunshine_i10k-123125.htm#488621 Filing: 000168316826002644 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 5.98 million Exact value Exact value: -5975352 USD 2025-01-01 – 2025-12-31: -5975352 USD Inspect Net Income Open source Share or cite Citation for Net Income · SUNSHINE BIOPHARMA INC. · 2025-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Net Income: -5975352 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -5975352 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316826002644/sunshine_i10k-123125.htm#471851 Filing: 000168316826002644 The citation records this snapshot. The page link may show a newer release later.	−USD 5.33 million Exact value Exact value: -5331073 USD 2025-01-01 – 2025-12-31: -5331073 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SUNSHINE BIOPHARMA INC. · 2025-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Operating Cash Flow: -5331073 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5331073 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316826002644/sunshine_i10k-123125.htm#485102 Filing: 000168316826002644 The citation records this snapshot. The page link may show a newer release later.	USD 174,491 Exact value Exact value: 174491 USD 2025-01-01 – 2025-12-31: 174491 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SUNSHINE BIOPHARMA INC. · 2025-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Capital Expenditure: 174491 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 174491 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316826002644/sunshine_i10k-123125.htm#488159 Filing: 000168316826002644 The citation records this snapshot. The page link may show a newer release later.	−USD 5.51 million Calculation and evidence -5331073 − 174491 USD Exact free cash flow: -5505564 USD 2025-01-01 – 2025-12-31: -5331073 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 174491 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SUNSHINE BIOPHARMA INC. · 2025-12-31 SUNSHINE BIOPHARMA INC. (edgar:1402328) Free cash flow: -5505564 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1402328?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -5331073 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316826002644/sunshine_i10k-123125.htm#485102 Filing: 000168316826002644 Input fundies:CapitalExpenditure: 174491 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1402328/000168316826002644/sunshine_i10k-123125.htm#488159 Filing: 000168316826002644 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

105 filings · 3,790 latest values · 3,814 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001402328, 1402328, SBFM, SBFMW, edgar:1402328

Also known as Mountain West Business Solutions, Inc, SUNSHINE BIOPHARMA, INC., SUNSHINE BIOPHARMA INC., SUNSHINE BIOPHARMA, INC, SUNSHINE BIOPHARMA, INC., Sunshine Biopharma Inc., Sunshine Biopharma, Inc, Sunshine Biopharma, Inc., mountain state business solutions,inc, mountain west business solutions,inc

SUNSHINE BIOPHARMA INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation